Therefore, this study aimed to use a specific compound, andrographolide, in GBM as the primary source of the drug by targeting the upstream and downstream regulators of the c-Myc signaling pathway such as MAPK/ERK1/2, Wnt/β-catenin, Hedgehog, Hippo, p53, NF-Κb, STAT, and p13-K/AKT/ERK [19]. The gene discussed is MYC; the disease is glioblastoma.